Every now and then, a new peptide crosses our collective transom and shortly afterward, a press release or article arrives with the news heds declaring a number: 20% weight loss, 24% weight loss, “next-generation” whatever. The number seems to be real. What’s also real is everything we rely upon to create that number. Maybe it was discovered in the first phase of a study, where the compound was simply compared against a placebo. Maybe it’s a measurement that correlates with the real end goal sought. Or maybe a third of the participants didn’t return to get remeasured during the last year of the requisite study. These are the questions we should be asking about those numbers.
Know What Each Trial Phase Can Prove
Phase 1 study hardly provides any information on the effectiveness of a drug. It typically involves 20 to 80 healthy individuals and aims to determine the drug’s absorption, distribution, metabolism, excretion, and toxicity. Phase 2 involves a larger group of patients and efficacy data starts to become available but the sample size is not large enough to identify potential rare adverse reactions or to make strong conclusions on long-term safety. In phase 3, you finally get enough patients for the findings to be statistically significant, patients are randomly assigned to a comparator, and rare adverse reactions can be detected because there are so many participants.
None of this context is particularly attractive in a press release. “Results indicate a 15% improvement in X” might be the entirety of the data shared with the media after a phase 1 trial. It sounds much the same coming from a 40-patient phase 2 trial or a 2,000-patient phase 3 trial, but given the small number of patients and the lack of comparison to a placebo group, that first-phase result is almost completely meaningless. If the first phase and the number of patients in the study aren’t mentioned in the first paragraph, you probably should stop reading.
Surrogate Endpoints Aren’t Proof Of Benefit
Changes in percentage body-weight and HbA1c levels are indirect measurements. They are effective, easily quantifiable, and they are related to the results that truly matter; nevertheless, they are not the results themselves. Results such as major adverse cardiovascular events, all-cause mortality, or hospitalization are known as primary outcomes. A drug could considerably improve a surrogate endpoint and still present no primary outcome advantage or even a primary outcome detriment after a sufficiently large primary-outcome study is completed.
This distinction is important since the majority of the information available for new treatments are surrogate results, as primary-outcome studies require more time and resources to be completed. A treatment solution qualifies as having “proven benefit” only after an outcomes study supports that it has. Before that, the data is considered to be a favorable trend, but not a definitive result.
Read The Variance, Not Just The Mean
A headline such as “24% average weight reduction” is not very informative by itself. You also need to know the confidence interval, responder distribution, and completion rate. Averages obscure a vast amount of variance – some subjects might lose 35% of their weight and some might lose very few pounds, with the average falling in the middle, all without indicating to you which of those groups you’re likely to fall into.
The completion rate poses an equivalently important puzzle. The way most trials report results can be divided into two forms: “intention-to-treat,” in which all subjects who began the trial are included whether or not they completed it, and “per-protocol,” which analyzes only completers. A drug with a lot of people dropping out can look spuriously effective in a per-protocol analysis, since the people who drop out are disproportionately likely to be non-responders or intolerant people. If you see a strong per-protocol result and a weak intention-to-treat result, that discrepancy is revealing something to you about how well the drug would be tolerated by real-world patients. The headline number is not letting on.
Appetite Suppression and Energy Expenditure Are Different Levers
Most drugs in this category work through incretin mimetics, primarily GLP-1 receptor agonism, which slows gastric emptying and boosts satiety signaling to reduce intake. Dual agonists layer GIP receptor activity on top of GLP-1, which appears to improve insulin sensitivity and may add modest efficacy over single-target agents. Triple agonists go further still by adding glucagon receptor agonism — and this is the genuinely different piece mechanistically. Glucagon receptor activity is linked to increased energy expenditure and basal metabolic rate, not just reduced intake. That’s a separate physiological lever from appetite suppression alone.
The Retatrutide Peptide is currently the clearest example in development of this triple-agonist approach. Its phase 2 data have drawn attention because the reported weight-loss figures outpace what’s typically seen with dual agonists, and the proposed mechanism — glucagon receptor activity driving expenditure rather than simply suppressing appetite — is theoretically distinct from earlier agents. But phase 2 is still phase 2. Retatrutide hasn’t yet completed confirmatory phase 3 outcomes trials, and mechanistic plausibility can’t substitute for that data. Early numbers are worth treating as a hypothesis, not a conclusion.
For comparison, tirzepatide’s SURMOUNT-1 trial — published in the New England Journal of Medicine in 2022 — found the 15 mg dose produced a mean body-weight reduction of 20.9% versus placebo at 72 weeks in overweight or obese adults without diabetes. That’s a real, regulator-accepted benchmark. It’s tempting to set a newer agent’s phase 2 number beside it and call a winner, but cross-trial comparisons are shaky — different populations, different durations, different endpoint definitions. Treat the SURMOUNT-1 figure as a reference point, not a scoreboard.
Specific Safety Signals Worth Hunting For
Do not accept a general statement in a summary paragraph like “generally well tolerated.” Search the trial report or label for these specifics: Gastrointestinal upsets are a problem for the entire class: nausea, vomiting, diarrhea, particularly on dose escalation. If the trial doesn’t detail how doses were titrated up, the authors are probably steering you away from the rough spots. Gallbladder and pancreatic events occur at low but not insignificant rates across incretin-based therapies and should not be buried in the fine print. Gastroparesis turns up in post-marketing data for other agents; it should not be taken off the table here.
Thyroid C-cell growths or cancer were seen in rodent trials with GLP-1-based drugs. Human relevance is unknown. The gap between animal signal and clinical human findings is a very different thing from an exculpation. It should be stated plainly, not glossed over with vague language. Preserving lean mass is the other newly recognized safety concern, and it’s a concomitant problem with rapid weight loss. Losing fat mass fast often comes with losing meaningful amounts of fat-free mass, and that has implications for metabolic health and physical function that a percent-body-weight number doesn’t capture at all.
Where To Actually Find The Information
There is a hierarchy of sources, and each step down loses credibility. Peer-reviewed randomized trial data is at the top – published, replicated where possible, and subject to editorial review. Below that is a regulatory label or review document, which is thorough but reflects the sponsor’s submitted data package. Below that, a conference abstract – often preliminary, frequently missing methodological detail, sometimes revised or contradicted by the eventual full publication. Below that, a company press release, which is a marketing document first and a data summary second. And at the bottom social media testimonial, which carries essentially no evidentiary value regardless of how convincing the before-and-after looks.
A practical step almost nobody takes: check ClinicalTrials.gov directly. Look at whether a trial is registered, what its pre-specified primary endpoint was before it started, and whether the actual reported result matches that pre-specified endpoint or has quietly shifted to a secondary one that looked better. Also check completion dates. It’s common to find trials that finished years ago with no published results anywhere – that’s a silence worth noting, because unpublished negative results are still results.
The Compounded and Gray-Market Problem
A significant amount of consumer harm in this space comes not from approved drugs, or even from drugs going through a clinical trial subjected to some regulatory oversight, but from batches of compounds manufactured by unknown labs, typically described as “research chemicals” where someone in an unregulated environment makes the decision to ingest a novel compound entirely of their own volition. These compounds often have purportedly specific purity percentages shipped along with them. But a one-page PDF that comes in a package and lists a percentage – well, it tells you one thing about what a lab found in one sample of what they submitted for analysis. It does not tell you about sterility. It doesn’t tell you about consistency across manufacturing. Purity documentation is not regulatory approval, and treating it as equivalent is how people end up dosing themselves with an unregulated substance based on a one-page PDF.
Individual Variability and What Happens After You Stop
Averages observed in clinical trials should be interpreted as trends rather than precise measures for all individuals. The baseline Body Mass Index (BMI), prevalence of diabetes, specific genetics, level of adherence and dietary habits will likely influence the response different patients will have to the same therapy. If you see that the average weight loss is about 20%, it is definitely not a sure forecast for you but a rough estimate that a group of people could potentially show.
Lastly, the “after” phase of the drug treatment is often neglected, but the inability of approved drugs to form a long-term solution demands the most attention for those with a sincere interest in managing their weight. Weight regain following treatment discontinuation is likely common for most of the late-stage clinical candidates in this field. That’s why when you read about protein recommended in conjunction with these treatments, or resistance training, it’s not about looking better in your clothes. It’s about lean mass and metabolism, which are key if you truly are bent on preventing the same cycle from continuously repeating itself.
A Six-Question Checklist
Before you believe any claim about a new therapy, evaluate it using these:
- Which phase trial did this data come from, and how many people were in the trial?
2. Is this a stand-in measure or a real clinical outcome?
3. How many dropped out, and are these the most optimistic conclusions possible or the usual-care results?
4. Does the purported action of the drug line up with its design for appetite or for energy, and does the claim match the science?
5. How seriously should you take the source, and can you get to the original information yourself?
6. Is this compound compounded or gray-market, or has it been through a regulatory process?
None of this is over your head. You don’t need a medical degree. You just need to learn how to look past the surface number and that’s a skill you can perfect.